Find verified Atogepant API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Atogepant for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Atogepant API.
Alternate Names: Qulipta, MK-8031, AGN-241689, Aquipta
CAS No: 1374248-81-3
PubChem CID: 72163100
Mol Formula: C29H23F6N5O3
Mol Weight: 603.5 g/mol
IUPAC Name: (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6′-5, -Show More
Therapeutic use: Migraine preventive agents
Commercial / Development Status: Commercial APIs
Source / Manufacturing Origin: Synthetic APIs
API Description: Atogepant is an oral antagonist of calcitonin gene-related peptide (CGRP) receptors indicated for the prevention of episodic migraine headaches. It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021. While its approval was predated by two other members of the same drug family, namely [ubrogepant] and [rimegepant], these agents are indicated only for abortive migraine therapy - atogepant is novel in that it is the first and only oral CGRP antagonist approved for preventative use in migraine. In December 2022, atogepant received Health Canada approval for the prevention of episodic migraine in adults. It also received approval for preventive treatment of adult migraine by the EMA in August 2023. In patients requiring preventative migraine therapy, current practice guidelines recommend the use of certain anti-epileptic medications (e.g. valproic acid or topiramate) or beta-blockers (e.g. propranolol), all of which can be associated with significant adverse effects. The "gepants" family of drugs, including atogepant, are comparatively well-tolerated and may provide a desirable treatment option for patients struggling with adverse reactions to other preventative therapies.
